VANCOUVER, British Columbia, Nov. 17 /PRNewswire-FirstCall/ -- ProtoKinetix, Inc. , a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that it has entered into a collaborative research agreement with a global multi-billion dollar company that provides products and services to pharmaceutical and biotechnology companies, as well as academic and research institutions. This company is recognized worldwide as one of the leading innovators of cell and tissue engineering. Due to the extreme sensitivity and highly competitive nature of this industry, the company has requested that, at this time, their name be kept confidential.
ProtoKinetix has a patented family of molecules (AAGP(TM)) that have clearly demonstrated a superior ability to protect cells and tissues subjected to hostile conditions. This collaboration will provide a platform to develop cell preservation formulations for specific applications of AAGP(TM) in a wide range of cell and tissue therapies.
Cell therapy is one of the fastest growing approaches to the treatment of disease. The survival of cells is an essential component for the success of these therapies.
About ProtoKinetix, Inc.
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the company about the broad range of applications for AAGP(TM) products. For more detailed information, please visit http://www.protokinetix.com.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward- looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.
CONTACT: ProtoKinetix, Inc., +1-604-687-9887, info@protokinetix.com; or
Investor Relations, Rick McCaffrey of OTC Financial Network for
ProtoKinetix, Inc., +1-781-444-6100 ext. 625, rick@otcfn.com
Web site: http://www.protokinetix.com/
